Unmet Need: Address the significant Alzheimer's market and the fact that there are currently no approved drugs specifically targeting this novel kinase.
De-risked Asset: A robust discovery campaign pioneered by an established biotech team in a listed company, involving over $15M in prior investment.
Clear Path Forward: We have a detailed, cost-effective plan to advance RN-077 into the clinic.
Asset: Global rights to a novel, pre-clinical therapeutic (RN-077) and its back-up compound (RN-081).
Mechanism: Differentiated, upstream mechanism of action with first-in-class potential.
Modality: Lower-cost oral small molecule with potential for combination therapy.
Team: Proven, focused, and experienced leadership.
The Ask: Seeking funding to initiate IND-enabling research for clinical advancement.
If you are an investor or business development professional seeking further information on this exclusive opportunity, we encourage you to request our pitch deck through the online form or by contacting us via the 'Contact Us' button below.